Diversification Re-engineered

Multi Asset Tactical View: November 2026

We are selectively positive on equities and commodities but cautious on bonds. In terms of equity sectors, we think biotech offers value amid M&A activity.

October: Rotation at play

October was a turbulent month for global equities, with Middle East tensions and renewed concerns over AI financing and valuations weighing on sentiment. These factors prompted a rotation from technology towards defensive and previously unloved areas. The UK and Europe posted modest gains, while the US edged lower, Japan underperformed and emerging markets fell sharply. Energy, consumer staples and health care advanced, while technology lagged. Global bonds recovered some of September’s losses as safe-haven demand lowered yields. Brent rose sharply on Hormuz supply risks, while gold fell below USD 3,900 as strong US data fuelled expectations of a December US Federal Reserve rate hike. Since month-end, some risks have been priced out: the clear US midterm results eased political uncertainty and oil retreated on hopes of de-escalation with Iran.

Our take: Selectively constructive

We remain constructive on global equities, as earnings have proven resilient, despite higher rates and renewed doubts about the AI investment cycle. In the US, the earnings backdrop remains supportive, but elevated valuations and concentration in AI-related stocks call for selectivity. We stay positive on Japan, backed by earnings upgrades and accommodative real rates, and maintain a modestly positive view on euro zone equities. Emerging markets continue to offer attractive valuations and earnings, despite greater sensitivity to the technology cycle.

In fixed income, we remain cautious based on systematic factors, although fundamentally yields are at increasingly attractive levels. Government bonds also provided renewed diversification during the recent equity sell-off. But sticky inflation and fiscal pressures caution against too constructive a stance for now. We also stay cautious on US high yield and emerging market hard-currency debt, despite some support from the economic backdrop. We remain constructive on commodities. Oil benefits from supply disruption, while constrained supply supports copper. We are more cautious on gold, as high real yields and a strong US dollar remain headwinds, despite longer-term support from central bank purchases and fiscal concerns. In currencies, we favour the dollar, supported by better carry, while stretched valuations limit further upside.

Tactical asset allocation views summary
These views reflect a short-term time horizon showing the direction and conviction of the team’s analysis based on both fundamental and systematic indicators. These views are independent of individual portfolio construction considerations.

Source: Bloomberg Finance L.P.; data as of 30 October 2026. Past performance does not predict future returns. Global equities are represented by MSCI AC World Daily TR, Global sovereign by FTSE World Government Bond Index – Developed Markets in USD, Commodities by Bloomberg Commodity Index, Currencies (USD) by Bloomberg Dollar Spot, US equities by S&P 500 Index, Euro-zone equities by MSCI EMU Index (EUR), Japanese equities by TOPIX Index (JPY), Emerging markets by MSCI EM NR, US treasuries by J.P. Morgan US Government Bond Index, UK gilts by J.P. Morgan UK Government Bond Index, Euro-zone sovereign by J.P. Morgan EMU Investment Grade Index, US high yield by Bloomberg U.S. Corporate High Yield, EM fixed income by J.P. Morgan EMBI Plus Index, Oil by S&P GSCI Crude Oil, Copper by BBG Copper TR, Gold by GOLD SPOT $/OZ. For currencies, the US dollar (USD) and the British pound (GBP) are represented by each respective currency vs. the euro (EUR) as well as the USD vs. the Japanese yen (JPY).

Theme of the Month: Biotech equities

Big pharma faces patent expiries that could affect more than USD 500 billion in drug sales between 2026 and 2032, peaking at USD 158bn in 2031. To rebuild pipelines drugmakers are buying biotech innovation: biopharma merger and acquisitions in the first half of 2026 nearly equaled the full-year 2025 total Yet biotech valuations remain below their long-term average, warranting a closer look at the sector.

Patent expiries: average annual sales at risk to more than double in 2026-2032 compared with 2014-2025

Source: Evaluate - 2014-2025: World Preview 2023 (June 2023); 2026-2032: Norstella forecasting data provided by Evaluate, as published by PharmaVoice (8 October 2026). M&A: IQVIA, "Biopharma M&A: Mid-year 2026 update" (8 July 2026; majority-stake deals of USD 250m or more). Valuation: FactSet, S&P Biotechnology Industry Index, 1-year forward P/E of 17.7x vs. 19.8x average since 1996, as at 30 June 2026. "Sales at risk" = worldwide prescription sales in the year before patent expiry, allocated to the year of expiry; it is potential exposure to generic competition, not expected revenue loss. Averages: USD 75bn a year in 2026-2032 vs. USD 34bn in 2014-2025; 2023-2025 values are forecasts from the 2023 edition and the two editions differ (e.g. 2027: USD 80bn vs. USD 44bn). Total 2026-2032: USD 527bn (sum of the plotted values). Curve: least-squares exponential fit through all plotted values (about 6% p.a.); a descriptive fit, not a forecast. Forecasts are not a reliable indicator of future results.

Chart of the month: Rotation, not yet capitulation
Defensive stocks took the lead as momentum reversed in October
MSCI World Momentum and Minimum Volatility indices, NTR USD, indexed (30 Sep 2026 = 100)

Source: Bloomberg Finance L.P., Allianz Global Investors, daily data from 30 Sep 2026 to 30 Oct 2026 as at 30 Oct 2026. Net total returns in USD, rebased to 100. Investors cannot invest directly in an index. The information above is provided for illustrative purposes only, it should not be considered a recommendation to purchase or sell any particular security or strategy or as investment advice. Past performance, or any prediction, projection or forecast does not predict future returns.

October saw a notable shift in equity factor leadership. The MSCI World Momentum Index, which has a significant tilt towards the technology and AI-related stocks that had led markets in recent months, fell 8.3% over the month, while the MSCI World Minimum Volatility Index gained 6.0%. The resulting gap of around 14 percentage points appears to reflect growing questions about whether the heavy investment in AI will deliver the expected returns, and pressure built towards month-end as tech earnings disappointed and equity volatility rose. Investors seemed to favour more defensive areas of the market, which tend to carry a larger weight in minimum volatility portfolios. As losses were largely concentrated in a relatively small group of large-cap names, the broader market proved more resilient than the headlines might suggest. While the sell-off points to increased nervousness, we would not necessarily read it as a fundamental turning point, as the longer-term case for AI still looks broadly supported in our view. The episode does, however, underline how strongly the market is currently focused on this single theme.

Investing involves risk. The value of an investment and the income from it will fluctuate and investors may not get back the principal invested. Past performance is not indicative of future performance. This is a marketing communication. It is for informational purposes only. This document does not constitute investment advice or a recommendation to buy, sell or hold any security and shall not be deemed an offer to sell or a solicitation of an offer to buy any security.

The views and opinions expressed herein, which are subject to change without notice, are those of the issuer or its affiliated companies at the time of publication. Certain data used are derived from various sources believed to be reliable, but the accuracy or completeness of the data is not guaranteed and no liability is assumed for any direct or consequential losses arising from their use. The duplication, publication, extraction or transmission of the contents, irrespective of the form, is not permitted.

This material has not been reviewed by any regulatory authorities. In mainland China, it is for Qualified Domestic Institutional Investors scheme pursuant to applicable rules and regulations and is for information purpose only. This document does not constitute a public offer by virtue of Act Number 26.831 of the Argentine Republic and General Resolution No. 622/2013 of the NSC. This communication's sole purpose is to inform and does not under any circumstance constitute promotion or publicity of Allianz Global Investors products and/or services in Colombia or to Colombian residents pursuant to part 4 of Decree 2555 of 2010. This communication does not in any way aim to directly or indirectly initiate the purchase of a product or the provision of a service offered by Allianz Global Investors. Via reception of this document, each resident in Colombia acknowledges and accepts to have contacted Allianz Global Investors via their own initiative and that the communication under no circumstances does not arise from any promotional or marketing activities carried out by Allianz Global Investors. Colombian residents accept that accessing any type of social network page of Allianz Global Investors is done under their own responsibility and initiative and are aware that they may access specific information on the products and services of Allianz Global Investors. This communication is strictly private and confidential and may not be reproduced. This communication does not constitute a public offer of securities in Colombia pursuant to the public offer regulation set forth in Decree 2555 of 2010. This communication and the information provided herein should not be considered a solicitation or an offer by Allianz Global Investors or its affiliates to provide any financial products in Brazil, Panama, Peru, and Uruguay. In Australia, this material is presented by Allianz Global Investors Asia Pacific Limited (“AllianzGI AP”) and is intended for the use of investment consultants and other institutional/professional investors only, and is not directed to the public or individual retail investors. AllianzGI AP is not licensed to provide financial services to retail clients in Australia. AllianzGI AP is exempt from the requirement to hold an Australian Foreign Financial Service License under the Corporations Act 2001 (Cth) pursuant to ASIC Class Order (CO 03/1103) with respect to the provision of financial services to wholesale clients only. AllianzGI AP is licensed and regulated by Hong Kong Securities and Futures Commission under Hong Kong laws, which differ from Australian laws.

This document is being distributed by the following Allianz Global Investors companies:
Allianz Global Investors GmbH, an investment company in Germany, authorized by the German Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin); Allianz Global Investors (Schweiz) AG; in HK, by Allianz Global Investors Asia Pacific Ltd., licensed by the Hong Kong Securities and Futures Commission; in Singapore, by Allianz Global Investors Singapore Ltd., regulated by the Monetary Authority of Singapore [Company Registration No. 199907169Z]; in Japan, by Allianz Global Investors Japan Co., Ltd., registered in Japan as a Financial Instruments Business Operator [Registered No. The Director of Kanto Local Finance Bureau (Financial Instruments Business Operator), No. 424], Member of Japan Investment Advisers Association, the Investment Trust Association, Japan and Type II Financial Instruments Firms Association; in Taiwan, by Allianz Global Investors Taiwan Ltd., licensed by Financial Supervisory Commission in Taiwan; and in Indonesia, by PT. Allianz Global Investors Asset Management Indonesia is licensed and supervised by Indonesia Financial Services Authority (OJK). Investment through mutual funds contains risk. Before deciding to invest, prospective investors must read and understand the prospectus. Past performance does not guarantee/reflect an indication of future performance.

AdMaster 6119479

Allianz Global Investors

You are now leaving this website and being redirected to the below website. This does not imply any approval or endorsement of the information by Allianz Global Investors contained in the redirected website nor do Allianz Global Investors accept any responsibility or liability in connection with contained therein.